Supplementary Table 2 Clinical characteristics of 35 patients with verified systemic sclerosis, grouped according to pulmonary involvement and duration of disease.
From: Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
Group A (n = 12) | Group B (n = 23) | ||||||
|---|---|---|---|---|---|---|---|
Median | Range | (SEM) | Median | Range | (SEM) | ||
dSSc/lSSc | 8/4 | 5/18 | |||||
ACA/antiScl70 | 0/0 | 14/1 | |||||
Age (y) | 57 | 26–75 | (4.7) | 49 | 25–76 | (2.8) | ns |
Disease duration (y) | 1 | 1–1 | (0) | 2 | 1–49 | (2.3) | P < 0.01 |
Skin score (points) | 26 | 3–36 | (3.2) | 8 | 2–26 | (1.6) | P < 0.01 |
VC (%p) | 77 | 51–113 | (5.6) | 97 | 62–148 | (3.8) | P < 0.05 |
DLCO (%p) | 62 | 40–90 | (4.9) | 85 | 47–116 | (3.7) | P < 0.01 |
PAPsyst (mmHg) | 36 | 27–65 | (3.9) | 30 | 18–59 | (3.4) | ns |
GFR (%p) | 103 | 89–130 | (5.4) | 96 | 70–136 | (4.1) | ns |
Capillary density (loops/mm) | 4.2 | 2.4–6.9 | (0.6) | 5.5 | 2.2–8.4 | (0.4) | ns |